SNY (Sanofi S.A.) Rega marang bathi mangsa ngarep

Tandha merek Sanofi (SNY)

Under the leadership of Paul Hudson, Sanofi is focusing on immunology and vaccines while reducing its mass-market exposure. Opening the company's forward P/E ratio on GURU.Markets, we observe that the 9.20 metric determines this level. Stable demand for drugs protects the asset, although Asian supply chain disruptions and patent disputes create geopolitical risks.

Rega marang bathi mangsa ngarep: sanofi.com (SNY) kanggo 04.07.2022 - 14.11.2026

Rincian analitis lan laporan data perusahaan Sanofi Group (SNY)

- kuotasi lan prakiraan analis:
Rega saham Sanofi S.A.|SNY - Konsensus nilai wajar
- indikator valuasi pasar bisnis:
Nilai pasar Sanofi SA|SNY - Total Nilai Perusahaan
- data ekuitas miturut neraca:
Aset Bersih saben Siji Saham Sanofi|SNY - Nilai Buku Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku sanofi.com|SNY - Total Aset Bisnis
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Sanofi|SNY - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Sanofi|SNY - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Sanofi SA|SNY - Tanggungan jangka dawa|Utang jangka cendhak perusahaan Sanofi|Rasio cepet sanofi.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
SNY - Bathi resik|Bathi sing dikarepake Sanofi|SNY - Pangali rega marang bathi|Rega marang bathi mangsa ngarep Sanofi Aventis|SNY - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Sanofi SA|SNY - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Sanofi|SNY - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan sanofi.com|SNY - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sanofi
- rincian pendapatan lan dodolan emiten:
SNY - Volume dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan Sanofi S.A.|SNY - Rega marang dodolan|Rasio rega marang prakiraan pendapatan Sanofi SA
Ringkesan analitik perusahaan:Sanofi S.A.
Produk merek Sanofi

The operational efficiency of Sanofi (SNY) directly determines the market expectations captured by this indicator. The company's expected price-to-earnings ratio compares current market capitalization with projected earnings, revealing the degree of market optimism regarding future margins. An increasing ratio signals confidence in the growth strategy. The implementation of ESG standards and non-commercial drug supplies create long-term value, mitigating operational cost risks. The stability of this metric confirms the fundamental resilience of the business.

Analisis pesaing

Pangali Forward P/E LLY|ABBV (AbbVie Inc) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep AstraZeneca AB AZN|Novartis Pharma (NVS) - Rasio prakiraan rega marang bathi|MRK - Rega marang bathi mangsa ngarep|NVO: Rega marang bathi mangsa ngarep|AMGN: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep PFE|BMY (BMS) - Pangali Forward P/E|GSK Corp (GSK) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Takeda Pharmaceutical (TAK)|Teva Pharmaceuticals - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E RDY (Dr. Reddy's)|Pangali forward rega marang bathi Viatris Inc|ROIV - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Zai Lab Corp ZLAB|BHC: Pangali Forward P/E|cosmosholdingsinc.com (COSM) - Pangali Forward P/E